"Optic Neuritis Pipeline Insights, 2022" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Optic Neuritis market. A detailed picture of the Optic Neuritis pipeline landscape is provided, which includes the disease overview and Optic Neuritis treatment guidelines. The assessment part of the report embraces in-depth Optic Neuritis commercial assessment and clinical assessment of the Optic Neuritis pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Optic Neuritis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
The report provides insights into:
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.
This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
1. Report Introduction
2. Optic Neuritis
2.1. Overview
2.2. History
2.3. Optic Neuritis Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Optic Neuritis Diagnosis
2.6.1. Diagnostic Guidelines
3. Optic Neuritis Current Treatment Patterns
3.1. Optic Neuritis Treatment Guidelines
4. Optic Neuritis - DelveInsight's Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Optic Neuritis companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Optic Neuritis Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Optic Neuritis Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Optic Neuritis Late Stage Products (Phase-III)
7. Optic Neuritis Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Optic Neuritis Discontinued Products
13. Optic Neuritis Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
Detailed information in the report?
14. Optic Neuritis Key Companies
15. Optic Neuritis Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Optic Neuritis Unmet Needs
18. Optic Neuritis Future Perspectives
19. Optic Neuritis Analyst Review
20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
Table 1: Optic Neuritis Diagnostic Guidelines
Table 2: Optic Neuritis Treatment Guidelines
Table 3: Assessment Summary
Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5: Optic Neuritis Acquisition Analysis
Table 6: Assessment by Phase of Development
Table 7: Assessment by Product Type (Mono / Combination)
Table 8: Assessment by Stage and Product Type
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Assessment by MOA
Table 14: Assessment by Stage and MOA
Table 15: Assessment by Target
Table 16: Assessment by Stage and Target
Table 17: Optic Neuritis Late Stage Products (Phase-III)
Table 18: Optic Neuritis Mid Stage Products (Phase-II)
Table 19: Optic Neuritis Early Stage Products (Phase-I)
Table 20: Pre-clinical and Discovery Stage Products
Table 21: Inactive Products
Table 22: Dormant Products
Table 23: Discontinued Products
Figure 1: Disease Overview
Figure 2: History
Figure 3: Symptoms
Figure 4: Causes
Figure 5: Pathophysiology
Figure 6: Diagnostic Guidelines
Figure 7: Treatment Guidelines
Figure 8: Optic Neuritis companies collaborations, Licensing, Acquisition -Deal Value Trends
Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10: Optic Neuritis Acquisition Analysis
Figure 11: Assessment by Phase of Development
Figure 12: Assessment by Product Type (Mono / Combination)
Figure 13: Assessment by Stage and Product Type
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Assessment by MOA
Figure 19: Assessment by Stage and MOA
Figure 20: Late Stage Products (Phase-III)
Figure 21: Mid Stage Products (Phase-II)
Figure 22: Early Stage Products (Phase-I)
Figure 23: Pre-clinical and Discovery Stage Products
Figure 24: Inactive Products
Figure 25: Dormant Products
Figure 26: Discontinued Products
Figure 27: Unmet Needs
